Floatz logo

Olvi-Vec

SCLC, Extensive Stage

Newsoara HYK Biopharmaceutical (Shanghai) Co., Ltd.Phase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

290 Active assets in the SCLC, Extensive Stage cohort.

Asset / SponsorPhaseRating
Benmelstobart
Yayi He
Phase 4A
vx-970
National Cancer Institute (NCI)
Phase 2BBB
Adebelimab
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3BBB
Veliparib
Central European Society for Anticancer Drug Research
Phase 2BB
CIS-DIAMMINEDICHLOROPLATINUM II
National Cancer Institute (NCI)
Phase 4BB

View all 50 →

Same molecule, other indications

Olvi-Vec is also rated in:

peritoneal carcinomatosisDormant
CCC
Indicative ·
48 / 100
View asset →
fallopian tube cancerDormant
CC
Indicative ·
44 / 100
View asset →
ovarian cancerDormant
CC
Indicative ·
42 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →